Related Experiment Video

Updated: Mar 16, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K

Synergistic Potential of Linagliptin and Resveratrol in Mitigating Type-II Diabetes-Induced Nephropathy: A

Prashant Ghimiray1, P R Anand Vijayakumar1, G R Meghna1

  • 1Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India.

Current Diabetes Reviews
|March 14, 2026
PubMed

Insights

Linagliptin and resveratrol show promise in preventing diabetic nephropathy. Their combined use may offer enhanced protection against kidney damage by reducing inflammation and oxidative stress.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy is a major complication of diabetes mellitus.
  • Current treatments have limitations in fully preventing disease progression.
  • Linagliptin and resveratrol have demonstrated individual renoprotective effects.

Purpose of the Study:

  • To review the synergistic effects of linagliptin and resveratrol in diabetic nephropathy.
  • To explore their individual and combined mechanisms of action.
  • To assess their potential for enhanced renoprotection.

Main Methods:

  • Systematic literature analysis of resveratrol and linagliptin.
  • Critical review of antioxidant, anti-inflammatory, and anti-fibrotic mechanisms.
  • Examination of studies in diabetic animal models.

Main Results:

  • Linagliptin improves renal outcomes via incretin-dependent/independent pathways, reducing oxidative stress, inflammation, and AGE-RAGE axis activation.
  • Resveratrol activates AMPK/Nrf2, mitigates oxidative stress, and downregulates inflammatory markers (TNF-α, IL-1β).
  • Synergistic use may enhance glycemic control and offer superior protection against diabetic nephropathy.

Conclusions:

  • Linagliptin and resveratrol possess complementary renoprotective mechanisms.
  • Their combined administration may offer superior therapeutic benefits for diabetic nephropathy.
  • Further clinical investigation is warranted to confirm synergistic effects.
Keywords:
AMPK/Nrf2 pathwayDPP-4 inhibitorsDiabetic NephropathyLinagliptinResveratroltype II diabetes mellitus

More Related Videos

Preparation of Naringenin Solution for In Vivo Application08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

3.9K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
813
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
876
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
821
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.3K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K